329 related articles for article (PubMed ID: 19124832)
1. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
Cerboni C; Ardolino M; Santoni A; Zingoni A
Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
[TBL] [Abstract][Full Text] [Related]
2. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
3. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
[TBL] [Abstract][Full Text] [Related]
4. DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells.
Fernández-Sánchez A; Baragaño Raneros A; Carvajal Palao R; Sanz AB; Ortiz A; Ortega F; Suárez-Álvarez B; López-Larrea C
Epigenetics; 2013 Jan; 8(1):66-78. PubMed ID: 23235109
[TBL] [Abstract][Full Text] [Related]
5. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
Stojanovic A; Correia MP; Cerwenka A
Front Immunol; 2018; 9():827. PubMed ID: 29740438
[TBL] [Abstract][Full Text] [Related]
6. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
Kim Y; Born C; Bléry M; Steinle A
Front Immunol; 2020; 11():960. PubMed ID: 32582150
[TBL] [Abstract][Full Text] [Related]
7. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
8. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Giuliani E; Vassena L; Cerboni C; Doria M
Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
[TBL] [Abstract][Full Text] [Related]
9. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
11. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
Maccalli C; Scaramuzza S; Parmiani G
Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424
[TBL] [Abstract][Full Text] [Related]
12. Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands.
Domaica CI; Fuertes MB; Rossi LE; Girart MV; Avila DE; Rabinovich GA; Zwirner NW
EMBO Rep; 2009 Aug; 10(8):908-15. PubMed ID: 19498463
[TBL] [Abstract][Full Text] [Related]
13. The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells.
Talebian L; Fischer DA; Wu J; Channon JY; Sentman CL; Ernstoff MS; Meehan KR
Transfusion; 2014 Jun; 54(6):1515-21. PubMed ID: 24446786
[TBL] [Abstract][Full Text] [Related]
14. Mutual activation of CD4+ T cells and monocytes mediated by NKG2D-MIC interaction requires IFN-gamma production in systemic lupus erythematosus.
Yang D; Wang H; Ni B; He Y; Li J; Tang Y; Fu X; Wang Q; Xu G; Li K; Yang Z; Wu Y
Mol Immunol; 2009 Apr; 46(7):1432-42. PubMed ID: 19200602
[TBL] [Abstract][Full Text] [Related]
15. Stress Signal ULBP4, an NKG2D Ligand, Is Upregulated in Multiple Sclerosis and Shapes CD8
Carmena Moratalla A; Carpentier Solorio Y; Lemaitre F; Farzam-Kia N; Levert A; Zandee SEJ; Lahav B; Guimond JV; Haddad E; Girard M; Duquette P; Larochelle C; Prat A; Arbour N
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34873031
[TBL] [Abstract][Full Text] [Related]
16. NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica.
Dejaco C; Duftner C; Al-Massad J; Wagner AD; Park JK; Fessler J; Aigelsreiter A; Hafner F; Vega S; Sterlacci W; Grubeck-Loebenstein B; Tzankov A; Ness T; Boiardi L; Salvarani C; Schirmer M
Ann Rheum Dis; 2013 Nov; 72(11):1852-9. PubMed ID: 23417963
[TBL] [Abstract][Full Text] [Related]
17. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.
Groh V; Wu J; Yee C; Spies T
Nature; 2002 Oct; 419(6908):734-8. PubMed ID: 12384702
[TBL] [Abstract][Full Text] [Related]
18. NKG2D is a costimulatory receptor for human naive CD8+ T cells.
Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F
J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668
[TBL] [Abstract][Full Text] [Related]
19. NKG2D Defines a Subset of Skin Effector Memory CD8 T Cells with Proinflammatory Functions in Vitiligo.
Jacquemin C; Martins C; Lucchese F; Thiolat D; Taieb A; Seneschal J; Boniface K
J Invest Dermatol; 2020 Jun; 140(6):1143-1153.e5. PubMed ID: 31877315
[TBL] [Abstract][Full Text] [Related]
20. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.
Lundholm M; Schröder M; Nagaeva O; Baranov V; Widmark A; Mincheva-Nilsson L; Wikström P
PLoS One; 2014; 9(9):e108925. PubMed ID: 25268476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
